Login

Forgot password?
Sign up today and your first download is free.
REGISTER

Opioids

March 27, 2018 | Daily News

Senate health committee Chair Lamar Alexander (R-TN) on Monday (March 26) unveiled draft legislation to let FDA require opioids be sold in short-course supplies of unit-dose packages to curb overdoses.

March 22, 2018 | Daily News

During day one of the House Energy & Commerce health subcommittee’s two-day legislative hearing to discuss more than 20 bills intended to help stem the opioid crisis, lawmakers and FDA Commissioner Scott Gottlieb focused on legislation that would increase FDA’s footprint and authority in international mail facilities (IMFs).

March 22, 2018 | Daily News

Members of the House Energy & Commerce Committee vigorously debated Thursday (March 22) whether to loosen privacy protections for medical records related to substance abuse treatment -- a proposal that some industry groups say would improve coordination of care in Medicare.

March 21, 2018 | Daily News

Mental health advocates and Medicaid managed care plans are cheering the Trump administration's proposal to allow Medicaid to pay for substance abuse treatment in large residential facilities, but so far it has gotten little traction in Congress, and one industry analyst said its chances of passing remain less than 50 percent.

March 20, 2018 | Daily News

House Energy & Commerce ranking Democrat Frank Pallone (NJ) introduced legislation Tuesday (March 13) that would grant HHS and FDA more authority to refuse admission of controlled substances or other drugs into the United States if the agencies deem the products pose a health risk or are counterfeit.

March 19, 2018 | Daily News

President Donald Trump on Monday (March 19) announced his plan to combat the opioid crisis, which includes increasing federal funding for the development of non-addictive pain medicines, cutting nationwide opioid prescriptions by one-third over the next three years, and creating an educational campaign and commercials showcasing the harms of opioid abuse and addiction.

March 15, 2018 | Daily News

The House Energy & Commerce health subcommittee announced on Wednesday (March 14) the slate of 21 bills it intends to discuss during its two-day hearing on legislation that could help stem the opioid crisis.

March 08, 2018 | Daily News

The House Energy & Commerce health subcommittee will hold a two-day legislative hearing on March 21 and 22 to examine more than 20 bills intended to help combat the opioid crisis, the committee announced Thursday (March 8).

March 02, 2018 | Daily News

A group of 15 Democratic senators, led by Ed Markey (MA) and Sherrod Brown (OH), called on top insurers to revise their existing coverage policies in order to help stem the opioid epidemic.

March 02, 2018 | Daily News

In a Thursday (March 1) memo, Attorney General Jeff Sessions directed the Drug Enforcement Administration (DEA) to consider amending its regulations on manufacturing quotas for schedule I and schedule II substances, including prescription opioids.

March 02, 2018 | Daily News

CMS should more aggressively encourage lock-in programs that would restrict Medicare beneficiaries who are at risk of opioid addiction to a limited number of pharmacies or prescribers, top Republicans and Democrats on the House Ways & Means Committee said in a March 1 letter to CMS Administrator Seema Verma.

March 02, 2018 | Daily News

Congress’ Medicaid advisory commission is calling on HHS to clarify what the commission described as widespread confusion among providers and patients over a 46-year-old privacy law intended to protect the privacy of people treated for drug addiction.

March 01, 2018 | Daily News

The House Energy & Commerce health subcommittee will focus its next two legislative hearings on opioid bills aimed at enhancing addiction treatment and recovery, as well as legislation dealing with insurance coverage, E&C Committee Chair Greg Walden (R-OR) said during a keynote speech at the Chamber of Commerce’s Combating the Opioid Crisis forum Thursday (March 1).

March 01, 2018 | Daily News

A panel of industry stakeholders and addiction and medicine specialists raised concerns at a House hearing Wednesday (Feb. 28) that research could be stifled and opioid promotion increased under a bill that would amend the Controlled Substances Act to add a sixth scheduling category and another that would mandate 12 hours of opioid prescriber education.

February 28, 2018 | Daily News

Opioid-related hospitalizations increased between 2013 and 2015 as some states instituted Medicaid expansion, but the percentage of those where the patient was uninsured fell more sharply in expansion states, according to a report released Wednesday (Feb. 28) by the Center on Budget and Policy Priorities.

February 28, 2018 | Daily News

A bipartisan group of senators on Tuesday (Feb. 27) introduced updated opioid legislation that builds on the Comprehensive Addiction and Recovery Act signed into law in 2016.

February 27, 2018 | Daily News

The Department of Justice has launched a task force aimed at holding opioid manufacturers accountable for unlawful marketing practices and ensuring distributors, including pharmacies and physicians, obey Drug Enforcement Administration rules designed to prevent diversion and improper prescribing, DOJ announced Tuesday (Feb. 27).

February 27, 2018 | Daily News

The Pew Charitable Trusts says ensuring Medicare and Medicaid programs cover all approved medication-assisted treatment (MAT) and levels of care as laid out by the American Society for Addiction Medicine (ASAM) is one way Congress could help improve access to opioid use disorder treatment.

February 26, 2018 | Daily News

HHS Secretary Alex Azar on Saturday (Feb. 24) pledged to expand the use of medication-assisted treatments (MAT) to treat opioid addiction, telling the National Governor's Association that FDA will soon release two pieces of draft guidance aimed at boosting development of new therapies.

February 26, 2018 | Daily News

FDA's Office of Prescription Drug Promotion issued a warning to the maker of an abuse-deterrent opioid for allegedly understating the risks of the product, which included printing the limitations of abuse-deterrent technology below the benefits.

Pages